ClinicalTrials.gg
Active, not recruitingNCT06972264Updated Feb 12, 2026

Safety and Efficacy of VDPHL01 in Males With AGA

A Phase 3 interventional study of VDPHL01 and Placebo in Androgenetic Alopecia, AGA and Male Pattern Baldness, sponsored by Veradermics, Inc.. Active, not recruiting at 44 sites in United States. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Veradermics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Planned enrollment
11th of 203
480 · median 40
Started
2025
with 19 others
Phase 3
14 of 216
2 open now
Primary completion
2026-12
later than 23 of 62 live
Registered
193rd of 216
by date

Among the 216 studies in Alopecia with a site in United States, this one is the 11th largest by planned enrollment of the 203 interventional ones that give a count, is one of 20 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 23 of the 62 other live ones, and was the 193rd registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA).

AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness.

This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).

03

Conditions studied

  • Androgenetic Alopecia
  • AGA
  • Male Pattern Baldness

Browse trials for

Keywords

  • Hair Loss
  • Male Hair Loss
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male aged 18-65 years old;
  • Subject has a clinical diagnosis of mild to moderate AGA;
  • Subject is in good general health and has adequate renal and hepatic function;
  • Subject is willing to maintain at least 1/4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study;
  • Subject is willing and able to administer the test article as directed read, understand, and complete required questionnaires in English;
  • Subject is willing and able to swallow study drug whole;
  • Subject agrees to have a micro dot tattoo placed on their scalp;
  • Subject agrees to have this area photographed at study visits as indicated in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject has uncontrolled blood pressure or orthostatic hypotension;
  • Subject has symptoms or history of certain heart or thyroid conditions;
  • Subject has a history of or active hair loss due to conditions/diseases other than AGA;
  • Subject has a current or recent history of dietary or weight changes, including use of GLP-1 agonists;
  • Subject has been diagnosed with COVID-19 within 16 weeks of screening;
  • Subject has had previous radiation of the scalp;
  • Use of any of the following treatments within the indicated before screening:

    • Subject has used hormone replacement therapy or hormonal modulators within 6 months prior to screening
    • Subject has used oral treatments for hair growth or that can affect hair growth, including systemic retinoids, within 6 months of screening
    • Subject has used systemic calcium channel blockers or beta blockers within 12 weeks prior to screening
    • Subject has used systemic cimetidine, ketoconazole, diazoxide, or (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening
    • Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, injections, rich plasma within 6 months prior to screening
    • Subject has used any topical scalp treatments for hair growth within 12 weeks prior to screening
  • Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study;
  • Subject has any other condition that, in the investigator's opinion, interfere with the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    VDHPL01 BID

    VDPHL01 will be taken orally twice a day, once in the AM and once in the PM.

    Drug: VDPHL01

  • Experimental
    VDPHL01 QD and Placebo QD

    Placebo will be taken orally once a day in the AM or PM. VDPHL01 will be taken orally once a day in the AM or PM.

    Drug: VDPHL01

  • Placebo comparator
    Placebo BID with treatment extension to VDPHL01 BID

    Placebo will be taken orally twice a day, once in the AM and once in the PM for the first 6 months of the study. After month 6, VDPHL01 will be taken orally twice a day, once in the AM and once in the PM.

    Drug: Placebo

  • Placebo comparator
    Placebo BID with treatment extension to VDPHL01 QD and Placebo QD

    Placebo will be taken orally twice a day, once in the AM and once in the PM for the first 6 months of the study. After month 6, placebo will be taken orally once a day in the AM or PM. VDPHL01 will be taken orally once a day in the AM or PM.

    Drug: Placebo

Interventions

  • VDPHL01 Extended Release (ER) Tablet

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Changes in non-vellus Target Area Hair Counts (TAHC)

    Change from baseline in non-vellus TAHC using digital image analysis at Month 6.

    Time frame: Month 6

  2. Subjects Evaluation of Treatment Benefit

    Subjects will rate their treatment benefit by responding to a hair assessment scale. The proportion of subjects by each response category will be reported at Month 6.

    Time frame: Month 6

07

Study locations

44 sites
  • Site 73
    Birmingham, Alabama 35209, United States
  • Site 89
    Birmingham, Alabama 35244, United States
  • Site 77
    Phoenix, Arizona 85006, United States
  • Site 69
    Encino, California 91436, United States
  • Site 64
    Manhattan Beach, California 90266, United States
  • Site 93
    Northridge, California 91324, United States
  • Site 66
    Santa Monica, California 90404, United States
  • Site 94
    Thousand Oaks, California 91320, United States
  • Site 71
    Boca Raton, Florida 33486, United States
  • Site 86
    Coral Gables, Florida 33134, United States
  • Site 62
    Coral Gables, Florida 33146, United States
  • Site 99
    Miami, Florida 33173, United States
  • Site 54
    Ocala, Florida 34470, United States
  • Site 96
    Tamarac, Florida 33321, United States
  • Site 90
    Sandy Springs, Georgia 30328, United States
  • Site 61
    Chicago, Illinois 60611, United States
  • Site 53
    Clarksville, Indiana 47129, United States
  • Site 55
    Plainfield, Indiana 46168, United States
  • Site 79
    Leawood, Kansas 66211, United States
  • Site 52
    Louisville, Kentucky 40241, United States
  • Site 75
    New Orleans, Louisiana 70124, United States
  • Site 84
    Glenn Dale, Maryland 20769, United States
  • Site 87
    Rockville, Maryland 20850, United States
  • Site 80
    Chestnut Hill, Massachusetts 02467, United States
  • Site 59
    Quincy, Massachusetts 02169, United States
  • Site 68
    Clinton Township, Michigan 48038, United States
  • Site 83
    Troy, Michigan 48084, United States
  • Site 82
    Hickory, North Carolina 28602, United States
  • Site 92
    Huntersville, North Carolina 28078, United States
  • Site 72
    Cincinnati, Ohio 45236, United States
  • Site 57
    Portland, Oregon 97210, United States
  • Site 81
    East Greenwich, Rhode Island 02818, United States
  • Site 60
    Anderson, South Carolina 29625, United States
  • Site 95
    Hermitage, Tennessee 37076, United States
  • Site 76
    Austin, Texas 78746, United States
  • Site 51
    Austin, Texas 78759, United States
  • Site 74
    College Station, Texas 77845, United States
  • Site 67
    Dallas, Texas 75230, United States
  • Site 78
    Plano, Texas 75024, United States
  • Site 88
    San Antonio, Texas 78218, United States
  • Site 91
    Sugarland, Texas 77479, United States
  • Site 63
    Norfolk, Virginia 23502, United States
  • Site 85
    Norfolk, Virginia 23502, United States
  • Site 70
    Mill Creek, Washington 98012, United States
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
Mar 11, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06972264
Lead sponsor
Veradermics, Inc.
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Mar 11, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Reid Waldman, M.D.
study chair · Veradermics, Inc.
Timothy Durso, M.D.
study chair · Veradermics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VDPHL01

Start the discussion